These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11595564)

  • 1. Do vascular compartments differ in the development of chronic rejection? AT(1) blocker candesartan versus Ace blocker enalapril in an experimental heart transplant model.
    Richter M; Richter H; Skupin M; Mohr FW; Olbrich HG
    J Heart Lung Transplant; 2001 Oct; 20(10):1092-8. PubMed ID: 11595564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model.
    Richter M; Skupin M; Grabs R; Schramm D; Richter H; Olbrich HG
    J Heart Lung Transplant; 2000 Nov; 19(11):1047-55. PubMed ID: 11077221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy.
    Richter MH; Richter HR; Olbrich HG; Mohr FW
    Transpl Int; 2003 Jan; 16(1):26-32. PubMed ID: 12545338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model.
    Richter M; Westphal M; Maybaum B; Richter H; Skupin M; Mohr FW; Olbrich HG
    Transplant Proc; 1999; 31(1-2):106-7. PubMed ID: 10083031
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D; Porteri E; Bettoni G; Piccoli A; Castellano M; Muiesan ML; Pasini G; Guelfi D; Rosei EA
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
    Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
    Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enalapril and L-158809 on myocardial beta-adrenergic receptor density in transplanted rat hearts.
    Nakame T; Iguchi A; Tabayashi K
    Eur Surg Res; 2001; 33(4):297-302. PubMed ID: 11684837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats.
    Mackenzie HS; Ziai F; Nagano H; Azuma H; Troy JL; Rennke HG; Tilney NL; Brenner BM
    J Hypertens Suppl; 1997 Dec; 15(6):S21-5. PubMed ID: 9493123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
    Watanabe K; Juan W; Narasimman G; Ma M; Inoue M; Saito Y; Wahed MI; Nakazawa M; Hasegawa G; Naito M; Tachikawa H; Tanabe N; Kodama M; Aizawa Y; Yamamoto T; Yamaguchi K; Takahashi T
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S93-7. PubMed ID: 12693379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine does not enhance the development of accelerated coronary artery disease: experimental study in a rat cardiac transplant model.
    Richter M; Skupin M; Schramm D; Weinert M; Richter H; Mohr FW; Olbrich HG
    J Heart Lung Transplant; 2002 Apr; 21(4):425-34. PubMed ID: 11927218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonist improves age-related endothelial dysfunction.
    Kansui Y; Fujii K; Goto K; Abe I; Iida M
    J Hypertens; 2002 Mar; 20(3):439-46. PubMed ID: 11875311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury.
    Miyazaki M; Wada T; Shiota N; Takai S
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S21-5; discussion S33-4. PubMed ID: 10076917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.
    Szabo A; Lutz J; Schleimer K; Antus B; Hamar P; Philipp T; Heemann U
    Kidney Int; 2000 Mar; 57(3):982-91. PubMed ID: 10720951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
    Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
    Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
    Furukawa Y; Matsumori A; Hirozane T; Sasayama S
    Circulation; 1996 Jan; 93(2):333-9. PubMed ID: 8548907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.